Table 1 Characteristics of children with X-liked hypophosphatemia included in the study
From: Growth hormone treatment improves final height in children with X-linked hypophosphatemia
Parameters | Patients treated with rhGH | Patients not treated with rhGH | p |
|---|---|---|---|
Mean ± SD [min–max] or n (%) | Mean ± SD [min–max] or n (%) | ||
Number of patients | 34 | 29 | – |
Boys/girls, n (%) | 13 (38%)/21 (62%) | 10 (34%)/19 (66%) | 0.49 |
Birth weight, SDS | − 0.5 ± 2.0 | 0.4 ± 1.2 | 0.11 |
[− 5.0 to 3.5] | [− 1.5 to 2.0] | ||
Birth length, SDS | − 0.5 ± 1.9 | 0.5 ± 1.2 | 0.09 |
[− 5.0 to 3.0] | [− 1.7 to 1.9] | ||
Patients carrying a PHEX mutation, n (%) | 32 (94%) | 24 (86%) | 0.29 |
Age at XLH diagnosis, years | 3.4 ± 3.4 | 2.6 ± 2.6 | 0.32 |
[0.1–12] | [0.0–11.5] | ||
Duration of conventional therapy, years | 12.6 ± 4.9 | 14.0 ± 3.0 | 0.20 |
[3.0–21.8] | [5.5–17.8] | ||
Age at menarche, years | 13.4 ± 1.3 | 12.8 ± 0.8 | 0.15 |
[9.8–15.1] | [11.3–14.4] | ||
Age at rhGH start, years | 9.8 ± 3.4 | – | – |
[2.5–15.2] | |||
Duration of rhGH treatment, years | 4.4 ± 2.9 | – | – |
[0.6–12] | |||
Dose of rhGH (µg/kg/day) | 77.4 ± 14.5 | – | – |
– at the beginning of treatment | 77.4 ± 14.5 | ||
– at the end of treatment | 66.8 ± 20.5 | ||
Patients treated with a GnRH, n (%) | 15 (47%) | 2 (7%) | < 0.000 |